Dept. of Hematology, Oncology, Rheumatology UK-HD Most importantly: MRI accounts for a significant number of myeloma-defining events (MDE) and proofs to be a valuable tool.

CEPHEUS married CASSIOPEIA, had a daughter ANDROMEDA, whose beauty angered Poseidon, cursed to imprisonment with a sea monster, freed by PERSEUS, who eventually marries her. #daratumumab #Louvre

PE interventions might be profitable to the company margins but that implies changes which destroy the morale of business ventures. Perhaps acceptable in most industries, in the healthcare sector it can be cataclasmic.​​​​​​​​​​​​​​​​ Saddened by this cnn.com/2024/12/10/bus…

CONGRESS | #ASH24 | Susan Bal Susan Bal UAB shares extended FU data from the Phase I study of arlo-cel (BMS-986393) in heavily pretreated RRMM. ORR 87%, CR 53%, 150x10^6 CAR T cells ORR 91%, median DoR 18-mo, median PFS 18.3-mo, 12-mo OS 90%. Follow our live feed for more

Google just announced a breakthrough in quantum computing. It's called "Willow" - and it's making waves in the tech world. But buried in their announcement was something fascinating: A discovery that could reshape our understanding of computing itself...

IgGs over 10,000 have been known to be associated witth hyperviscosity although at levels 5000s or over, I have seen volume overload and pseudohypoNa. Any data on this? When I give car to this subset of pts- tolerance is poor. BNPs tend to run high

Any data on post transplant outcomes of patients who have not been exposed to any novel therapies in the contemporary era ? I know no one does this any more but curious. (Eg. PACE based induction)

About 30% of my pts achieve biochem CR with some of the bridging therapies (TCEs or HD mel) with the goal of CAR. (Most 4th LOT). Bridge administered post apheresis. I am opting to wait and monitor closely until progression (can preserve CARs upto 6 months). Any thoughts?

Any experience with CAR-T in AL for pts with profound dysautonomia? Supine SBP 170s, drops to 80s while standing, already on midodrine, fludrocortisone for hypotension (trial of pyridostigmine??)

AL question- post treatment initiation (eg.post asct) once uiFLC>iFLC,are we considering heme progression across the mathematical line to consider 50% increment to include negative difference and subsequent positive difference once iFLC>uiFLC? I think we should be

Waldenstrom/LPL defines disease progression biochemically as a 25% increment in IgM from best response but no minimum threshold considered in terms of an absolute value increase ? I know most of us go by clinical symptoms regardless

I have used anti-bcma therapy AFTER anti-gprc5d therapy more frequently these days; I see no issues with compromised responses even if done sequentially. (TCEs) for the most part. Any data presented for this?

70 + F with RRMM 4 prior lines, triple ref. Bcma sensitive, diagnosed with stage IIb melanoma on adjuvant pembro since 7/2024 planned x 1 yr. Concerned about cart with LD w flu/cy or benda ld (interrupt w adjuvant therapy efficacy), data for TCEs w CPI(?)

MM in >=4 LOT misbehaves a lot. Multiple pts on TCE or post cart even if not meeting progression by dFLC but consistent iFLC trend increment with end organ damage (mostly skeletal events).Perhaps the LC or m-spike criteria need adjustment allowing change of Rx before these events

6 prior LOTs. Anti-bcma cart failed (carvykti)-progressed x 2 months.Progressedx2 cycles of talq. Salvage Mel with a strong response, ‘consolidation’ elra x 1 and now on ‘maintenance’ selinexor (100mg weekly) thalidomide 400, in CR. No nausea, no fatigue. *Every* therapy matters

Went to pick up a prescription at the pharmacy and with my prescription card it was $467…. Cash price $63.40. Our healthcare and insurance system, and the Pharmacy benefit managers have created the biggest fraud machine I’ve ever seen.

Talquetamab dysguesia and xerostomia. Try this- Pilocarpine 2.5mg BID (upto 4 times a day) - can help

Important clinical pearl from Ronald Witteles! In cardiac AL, I check FLCs q-weekly in the first couple of months, and switch treatment if I sense plateau. “Every day matters” for the component of toxic cardiomyopathy from circulating FLCs.

Raj Chakraborty Ronald Witteles I like this approach. Depositing light chains is toxic, and the treatment of AL should be considered a quasi-emergency! Almost like renal failure in MM. #everydaymatters

PR after induction - "Go on" to ASCT OR "Hold on" for VGPR and then do ASCT. A dilemma which many of us face in practice. Our analysis from my previous workplace which answers this important question Indian Society of Haematology & Blood Transfusion IMAGe Pankaj Malhotra Uday Yanamandra ISBMT_UPDATES